Stanzi M le Roux1, Kirsten A Donald2,3, Max Kroon2,4, Tamsin K Phillips1,5, Maia Lesosky1, Liza Esterhuyse1, Allison Zerbe6, Kirsty Brittain1,5, Elaine J Abrams6,7, Landon Myer1,5. 1. From the Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine. 2. Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa. 3. Division of Developmental Paediatrics, Red Cross War Memorial Children's Hospital, Cape Town, South Africa. 4. Neonatal Service, Mowbray Maternity Hospital, Cape Town, South Africa. 5. Centre for Infectious Disease Epidemiology and Research (CIDER), School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. 6. ICAP at Columbia, Mailman School of Public Health. 7. College of Physicians and Surgeons, Columbia University, New York, New York.
Abstract
BACKGROUND: Elevated HIV viral load (VL) in pregnancy has been linked to increased risk of mortality, immunologic abnormalities, infectious morbidity and restricted growth among HIV-exposed uninfected (HEU) children, but little is known about effects on child development. METHODS: HIV-infected women initiating lifelong antiretroviral therapy (ART; tenofovir + emtricitabine + efavirenz) antenatally were followed from first antenatal visit through delivery and with their breastfed infants postpartum. Cognitive, motor and expressive language development (Bayley Scales of Infant and Toddler Development-Third Edition; delay defined as score <85) were assessed on a subset of HEU infants. HIV VL was measured at ART initiation, in third trimester and around delivery. Cumulative viremia in pregnancy was expressed as log10 VL copies × year/mL [viremia copy-years (VCY)]. Relationships between VCY and development were examined after adjusting for socioeconomic, behavioral and psychosocial confounders. RESULTS: Women (median pre-ART log10 VL 4.1, CD4 349 cells/mm) commonly reported adverse social circumstances (44% informal housing, 63% unemployed, 29% risky drinking). Among 214 infants (median age, 13 months; 53% male; 13% born <37 weeks' gestation), viremia predicted lower motor and expressive language, but not cognitive, scores in crude and adjusted analysis [per log10 VCY increase, αβ (95% confidence interval [CI]): motor, -2.94 (-5.77 to -0.11); language, -3.71 (-6.73 to -0.69) and cognitive -2.19 (-5.02 to 0.65)]. Increasing VCY also predicted higher relative odds of motor delay [adjusted odds ratio (aOR): 3.32; 95% CI: 1.36-8.14) and expressive language delay (aOR: 2.79; 95% CI: 1.57-4.94), but not cognitive delay (aOR: 1.68; 95% CI: 0.84-3.34). CONCLUSIONS: Cumulative maternal HIV viremia in pregnancy may have adverse implications for HEU child development.
BACKGROUND:Elevated HIV viral load (VL) in pregnancy has been linked to increased risk of mortality, immunologic abnormalities, infectious morbidity and restricted growth among HIV-exposed uninfected (HEU) children, but little is known about effects on child development. METHODS:HIV-infectedwomen initiating lifelong antiretroviral therapy (ART; tenofovir + emtricitabine + efavirenz) antenatally were followed from first antenatal visit through delivery and with their breastfed infants postpartum. Cognitive, motor and expressive language development (Bayley Scales of Infant and Toddler Development-Third Edition; delay defined as score <85) were assessed on a subset of HEU infants. HIV VL was measured at ART initiation, in third trimester and around delivery. Cumulative viremia in pregnancy was expressed as log10 VL copies × year/mL [viremia copy-years (VCY)]. Relationships between VCY and development were examined after adjusting for socioeconomic, behavioral and psychosocial confounders. RESULTS:Women (median pre-ART log10 VL 4.1, CD4 349 cells/mm) commonly reported adverse social circumstances (44% informal housing, 63% unemployed, 29% risky drinking). Among 214 infants (median age, 13 months; 53% male; 13% born <37 weeks' gestation), viremia predicted lower motor and expressive language, but not cognitive, scores in crude and adjusted analysis [per log10 VCY increase, αβ (95% confidence interval [CI]): motor, -2.94 (-5.77 to -0.11); language, -3.71 (-6.73 to -0.69) and cognitive -2.19 (-5.02 to 0.65)]. Increasing VCY also predicted higher relative odds of motor delay [adjusted odds ratio (aOR): 3.32; 95% CI: 1.36-8.14) and expressive language delay (aOR: 2.79; 95% CI: 1.57-4.94), but not cognitive delay (aOR: 1.68; 95% CI: 0.84-3.34). CONCLUSIONS: Cumulative maternal HIV viremia in pregnancy may have adverse implications for HEU child development.
Authors: Rachel S Gruver; Sumaya Mall; Jane D Kvalsvig; Justin R Knox; Claude A Mellins; Chris Desmond; Shuaib Kauchali; Stephen M Arpadi; Myra Taylor; Leslie L Davidson Journal: New Dir Child Adolesc Dev Date: 2020-07-03
Authors: Dvora L Joseph Davey; Stanzi M Le Roux; Kirsty Brittain; Kathryn Dovell; Steve Shoptaw; Amanda P Miller; Tamsin K Phillips; Allison Zerbe; Elaine J Abrams; Landon Myer Journal: AIDS Care Date: 2021-09-08
Authors: Thomas Struyf; Queen Dube; Elizabeth A Cromwell; Anna D Sheahan; Robert S Heyderman; Annelies Van Rie Journal: Eur J Paediatr Neurol Date: 2019-11-21 Impact factor: 3.140
Authors: Robert Ntozini; Jaya Chandna; Ceri Evans; Bernard Chasekwa; Florence D Majo; Gwendoline Kandawasvika; Naume V Tavengwa; Batsirai Mutasa; Kuda Mutasa; Lawrence H Moulton; Jean H Humphrey; Melissa J Gladstone; Andrew J Prendergast Journal: J Int AIDS Soc Date: 2020-05 Impact factor: 5.396
Authors: Maria L Alcaide; Violeta J Rodriguez; John M Abbamonte; Shandir Ramlagan; Sibusiso Sifunda; Stephen M Weiss; Karl Peltzer; Deborah L Jones Journal: Open Forum Infect Dis Date: 2019-10-09 Impact factor: 3.835
Authors: Ana R Pascom; Rosana Egg Pinho; Fernanda Rick; Nazle Mc Veras; Filipe de Barros Perini; Mariana V Meireles; Gerson F Pereira; Adele S Benzaken; Vivian I Avelino-Silva Journal: J Int AIDS Soc Date: 2019-11 Impact factor: 5.396